The peptide drug pipeline has expanded dramatically, driven by the commercial success of GLP-1 receptor agonists for obesity and diabetes. In 2025, over 80 peptide therapeutics are in clinical development across metabolic, oncology, rare disease, and immunology indications. This review catalogs the major pipeline programs and anticipated milestones.
- GLP-1 agonist market: ~$50 billion (2024)
- Total peptide therapeutics market: ~$70 billion (2024)
- Projected 2030 market: ~$150 billion (GLP-1 + next-generation agents)
- Obesity epidemic (42% US adult prevalence)
- Cardiovascular benefit demonstrations (SELECT trial)
- Oral formulation development
- Biosimilar entry (2025–2028)
- Expanded indications (MASH, CKD, heart failure, OSA)
| Agent | Company | Mechanism | Indication | Status | Expected Approval |
|---|
| Semaglutide 7.2 mg | Novo Nordisk | GLP-1R agonist | Obesity (high dose) | Phase 3 | 2026 |
| CagriSema | Novo Nordisk | GLP-1R + amylin | Obesity | Phase 3 | 2026 |
| Survodutide | Boehringer Ingelheim | GLP-1R/GCGR dual | Obesity, MASH | Phase 3 | 2026 |
| Retatrutide | Eli Lilly | GLP-1R/GIPR/GCGR triple | Obesity | Phase 3 | 2027 |
| Orforglipron | Eli Lilly | Oral GLP-1R agonist | Obesity, T2D | Phase 3 | 2027 |
| Amycretin | Novo Nordisk | GLP-1R/amylin dual | Obesity | Phase 3 | 2027 |
| Pemvidutide | Altimmune | GLP-1R/GCGR dual | Obesity, MASH | Phase 3 | 2026 |
| Danuglipron | Pfizer | Oral GLP-1R agonist | Obesity | Phase 3 | 2026 |
| Mazdutide | Innovent Biologics | GLP-1R/GCGR dual | Obesity | Phase 3 (China) | 2025 |
| Agent | Company | Mechanism | Indication | Status | Expected Approval |
|---|
| Semaglutide | Novo Nordisk | GLP-1R agonist | CKD (FLOW) | Phase 3 | 2025 |
| Semaglutide | Novo Nordisk | GLP-1R agonist | HFpEF | Phase 3 | 2025 |
| Tirzepatide | Eli Lilly | GLP-1R/GIPR dual | HFpEF | Phase 3 | 2026 |
| Survodutide | Boehringer Ingelheim | GLP-1R/GCGR dual | MASH | Phase 3 | 2026 |
| Tirzepatide | Eli Lilly | GLP-1R/GCGR dual | MASH | Phase 3 | 2026 |
| Agent | Company | Mechanism | Indication | Status | Expected Approval |
|---|
| Linaclotide | Ironwood | GC-C agonist | GI tumors | Phase 3 | 2025 |
| Somatoprim | Novartis | SSTR agonist | NET | Phase 3 | 2025 |
| PSMA-617 | Novartis | PSMA-targeted | mCRPC | Phase 3 | 2025 |
| Lu-177 DOTATATE | Novartis | SSTR-targeted | NET | Phase 3 | 2025 |
| Agent | Company | Mechanism | Indication | Status | Expected Approval |
|---|
| Vasopressin analog | Ferring | V1a/V2 agonist | DI | Phase 3 | 2025 |
| Cenderitide | Cardiolink | NPR-C agonist | AHF | Phase 3 | 2026 |
| Nesiritide | Scios | BNP analog | AHF | Phase 3 | 2025 |
| Agent | Company | Mechanism | Indication | Key Data |
|---|
| Octreotide SC | Novartis | SSTR agonist | Acromegaly | Phase 2 |
| Pasireotide LAR | Novartis | Pan-SSTR | Cushing’s | Phase 2 |
| Tesamorelin | Theratechnologies | GHRH analog | HIV lipodystrophy | Phase 2 |
| CagriSema | Novo Nordisk | GLP-1R/amylin | Obesity | Phase 2 |
| Retatrutide | Eli Lilly | GLP-1R/GIPR/GCGR | MASH | Phase 2 |
| Agent | Company | Mechanism | Indication | Key Data |
|---|
| Pegozafermin | 89bio | FGF21 analog | MASH | Phase 2 |
| Efruxifermin | Akero | FGF21 analog | MASH | Phase 2 |
| BMS-986278 | Bristol-Myers Squibb | LPAR1 antagonist | IPF | Phase 2 |
| GLP-1/GIP dual | Zealand | Dual agonist | Obesity | Phase 2 |
| Agent | Company | Mechanism | Indication | Key Data |
|---|
| OMB-157 | OmniAb | Bispecific antibody | CD20+ B-cell | Phase 2 |
| Ziltivekimab | Novo Nordisk | IL-6 inhibitor | CV | Phase 2 |
| BMS-986365 | Bristol-Myers Squibb | ADC | Solid tumors | Phase 2 |
| Agent | Company | Mechanism | Indication | Stage |
|---|
| Oral GLP-1/GIP | Roche | Dual oral agonist | Obesity | Phase 1 |
| Long-acting amylin | Zealand | Amylin analog | Obesity | Phase 1 |
| GCGR antagonist | Zealand | GCGR antagonist | MASH | Phase 1 |
| GLP-1/GIP/GCGR oral | Various | Triple oral | Obesity | Phase 1 |
| Peptide-drug conjugates | Various | Targeted delivery | Oncology | Phase 1 |
| Platform | Company | Description |
|---|
| Oral peptide | Orforglipron (Lilly) | Non-peptide GLP-1R agonist |
| Oral peptide | Danuglipron (Pfizer) | Non-peptide GLP-1R agonist |
| Oral peptide | EPIC (Novo) | Peptide with absorption enhancer |
| Depot formulation | Camurus | GLP-1 monthly/quarterly |
| Transdermal | Kindeva | GLP-1 patch delivery |
| Implantable | Various | 6-month peptide depot |
| Reference Product | Biosimilar Developers | Expected Entry |
|---|
| Liraglutide (Victoza) | Multiple | 2025–2026 |
| Semaglutide (Ozempic/Wegovy) | Multiple | 2031–2032 |
| Dulaglutide (Trulicity) | Multiple | 2027–2028 |
| Exenatide (Byetta) | Multiple | 2025 |
- 20–30% price reduction expected at launch
- Increased patient access globally
- Reduced manufacturing barriers
- Potential for biosimilar GLP-1/GIP dual agonists (2030+)
- Semaglutide (CKD indication)
- Semaglutide (HFpEF indication)
- Exenatide biosimilars
- Vasopressin analog (DI)
- CagriSema (obesity)
- Survodutide (obesity, MASH)
- Danuglipron (obesity)
- Tirzepatide (HFpEF)
- Tirzepatide (MASH)
- Retatrutide (obesity)
- Orforglipron (obesity, T2D)
- Amycretin (obesity)
- Oral GLP-1/GIP dual agonists
| Agent | 2025 Revenue | 2030 Projection |
|---|
| Semaglutide (Wegovy) | $15B | $25B |
| Tirzepatide (Zepbound) | $8B | $20B |
| CagriSema | — | $10B |
| Retatrutide | — | $8B |
| Orforglipron | — | $12B |
| Survodutide | — | $5B |
- Oral dominance: Oral formulations capture 40% of new prescriptions by 2030
- Biosimilar disruption: 15–20% revenue erosion for first-gen GLP-1s by 2028
- Combination therapies: GLP-1 + SGLT2 combinations emerge 2027+
- Indication expansion: Obesity agents move into CV, CKD, MASH, OSA
- Manufacturing scale: Peptide manufacturing capacity doubles 2025–2028
- Peptide synthesis scalability
- Supply chain constraints (glass vials, API)
- Cold-chain logistics for injectable formulations
- Cost of goods for large-scale production
- Long CVOT requirements for new indications
- Post-marketing safety surveillance
- Biosimilar interchangeability standards
- Global regulatory harmonization
- Payer coverage restrictions
- Prior authorization requirements
- Patient adherence (weekly vs daily)
- Competition from surgical and device-based treatments
The 2025 peptide drug pipeline is the most robust in history, with over 80 agents in clinical development. The incretin class dominates, with next-generation dual and triple agonists (CagriSema, survodutide, retatrutide) and oral formulations (orforglipron, danuglipron) expanding the treatment landscape. Biosimilar entry will reshape market dynamics, while new indications (MASH, CKD, OSA, HFpEF) drive sustained growth.
Deep dive: Read about Semaglutide vs Tirzepatide for head-to-head comparison, or explore Regulatory Pathways for FDA/EMA requirements.
Test yourself: Take the Drug Development Quiz or study with Clinical Trial Flashcards.
